Menu

Q1 FY22

lupin ltd.
Business, Equities, Markets, Research, Result Updates - October 3, 2022

Lupin ltd consolidated revenue fell by 14% YOY to Rs 3604 Cr.

In Q1FY23, Lupin ltd consolidated revenue fell by 14% YOY to Rs 3604 Cr.

Lupin limited is a multi-national pharmaceutical company based in Mumbai. The company specialises in branded and generic formulations, APIs and advanced drug delivery systems in biotechnology. It has 18 manufacturing sites and 9 R&D sites across the globe.

Lupin ltd consolidated revenue fell by 14.9% YOY to Rs 3604 Crores, in Q1FY23, due to subdued performance of its US business.EBITDA was down by 76% YOY to Rs 238 Crores. EBITDA margin falls by 1680 basis points.YOY to 6.6% due to raw martial inflation, higher employee spends and other expenses. Consequently , company reported a loss of Rs 89 Crores. As against of Rs 542 Crores profit a year ago. Company increasing market share, new product ,and scaling up of the Indian business indicate well for the company  performance.

Financial highlights :

In Q1FY23, lupin ltd consolidated revenue declined by 12.3% YOY and QOQ to Rs 3.74Crores.it is mainly due to muted performance in the US business. Revenue from the US business declined by 24.2% YOY and 28.7%Quarter On Quarter to Rs 1010 Crores due to inventory writw down , shelf stock adjustments and price erosion. Company s Indian revenue stood at Rs 1492 Crores which is down by 8.85 YOY and up by 10.4% QOQ DRIVEN BY A 9.9% Quarter on quarter driven by a 9.9 % QOQ growth in domestic formulations. API revenue grew by 3.7% YOY and 15.8% QOQ to Rs 255 Crores. While revenue from growth markets rose by 27.3% YOY and 11.2% QOQ to Rs 424 Crores.

Margins impacted due to raw material inflation:

Gross margin of company contracted by 720 basis points YOY to 55.3% as the company pared down inventories and took shelf shock adjustments on select products consequently; EBITDA fell by 76% YOY to Rs 238 Crores. Company owing to further price erosion in the US business and inflation in input materials. EBITDA margin thereby shrink  by  16.8% YOY to 6.4% reported a loss stood at Rs 89  Crores as against Rs 542 Crores .

Quarter highlights:  

Capex stood at Rs 161 Crores against Rs 106 Cr in Q1FY22 and Rs 158 Crores in Q4FY22. R&D expense was at Rs 348 Crores against Rs 374 Crores in Q1FY22 And Rs 344 Crores in Q4FY22. Total marketed generic products stood at 167. It launched cyclosporine ophthalmic in the US in the quarter. Current pipeline includes 54 FTF, OF Which 21 exclusive FTFs are awaiting for the USFDA approval. In India business, the company has a revenue run rate of more than Rs 1000 Crores. In cardiac and anti-diabetics .GI, pain and gynae grew in double digits.

Valuation:

The EPS was Rs. -1.96, compared to Rs. 10.15 in June 2021. The ROCE and ROE were at  -7.16% and -11.8%, respectively. The book value of a stock is Rs 267. The company’s asset turnover ratio was 0.73x. The scrip is trading at Rs.717, up by 5.40%. on Monday.

Astral Pipes posted a net profit of Rs. 96 Cr.

 

, , , , , , , 0 Comment
Read More
Tarsons Products earned Rs. 29 crores in net profit.
Business, Editorials, Equities, Markets, Research - September 16, 2022

Tarsons Products earned Rs. 29 crores in net profit.

Tarsons Products earned Rs. 29 crores in net profit.

On the high COVID-led base for Q1FY22, revenues fell 0.4% year on year. The total revenue was Rs 85 Cr and the net profit was Rs 29 Cr on a consolidated basis. The company reported a standalone revenue of Rs. 69 crore and a net profit of Rs. 20 crore.The operating profit was recorded at Rs. 44 Cr., with a pre-tax income of Rs. 39 Cr.

Margins shrink.

Domestic business fell around 6% YoY and 20% QoQ. The sequential decline was due to seasonality, with Q1 tending to be the weakest quarter. The company took a price hike in Q1FY23, which will begin to reflect in the next few quarters. The export business grew 11.1% YoY. This, coupled with elevated raw material prices, resulted in dragging gross margin down by 280bps YoY to 79.1%. The SG&A expenses grew 20.7% YoY, led by higher freight and promotion expenses. As a result, the EBITDA margin fell 760 basis points year on year (-680 basis points quarter on quarter) to 45.4%. The company expects to maintain healthy margins in the coming years thanks to improved product mix, increased contribution from new products, and in-house sterilisation, partially offset by higher costs associated with the start-up of new plants.

The PCR has received a good response from the customers in terms of quality. Specialised resin prices have stabilised, whereas packaging and paper costs have started declining. The revenues will be driven by growth in both domestic and export markets. We expect the company to maintain healthy margins in the coming years. The increased market share and strong growth in end-user industries will benefit the company. The major risk for the company is intensified competition and disruption in the distribution network.

Valuations:

The EPS was Rs. 5.54. The ROCE and ROE were at 35.3% and 27.4%, respectively. The stock was trading at a P/E ratio of 46x. The debt-to-equity ratio was 0.04x, whereas the asset turnover ratio was 0.72x. The interest coverage ratio stood at 33x. The scrip was trading at Rs.870, up by 1.02% on Thursday.

, , , , 0 Comment
Read More
Control Print declared a strong set of Q1FY23 results.
Business, Editorials, Equities, Markets, Research - September 16, 2022

Control Print declared a strong set of Q1FY23 results.

Control Print declared a strong set of Q1FY23 results.

The key highlight for the quarter was higher gross and EBIDTA margins YoY and QoQ on account of better product mix. The revenues grew by 19.7% YoY to 65.1 crore. Gross margins expanded QoQ by 440 bps to 63% vs. 58.7% in Q1FY22, which was mainly on account of a higher share of consumables in the overall revenues. which also led to EBIDTA margins coming in at 27.3% in Q1FY23 vs. 23.7% QoQ and 21.7% YoY. The PAT came in at 11.7 crore, up 105% YoY.

Strong financials:

The company, as of FY22, has an installed base of more than 15,000 printers. The consumable goods saw good traction during the quarter, while building materials, pharmaceuticals, and bearings also expanded their base. The company suffered a bit due to chip shortages and supply chain issues, but things will get back to normal in the coming 1-2 quarters. Dairy, healthcare, packaged food, cable, and FMCG also provided good contributions to business. The company is now focusing on developing software for customers so they can provide customized support to them. Telecalling is also helping companies acquire new customers. Imported raw materials account for 25-27% of total imports.The company has sold around 756 printers, of which CIJ printers are dominating the quantity with over 55–65% of the total share. The company is enjoying a higher installed base for printers as during COVID, printers’ sales were good. They offer seven different types of printers, of which CIJ and TIJ are the most common. The higher percentage of consumables in revenue resulted in higher gross and EBITDA margins. The current utilization level stands at 55-60 companies per hour. Capacity can be increased as needed.

Valuations:

The EPS was 7.40 rupees. The ROCE and ROE were at 18.8% and 15.3%, respectively. The stock was trading at a P/E ratio of 18.5x. The asset turnover ratio was 0.84x. The interest coverage ratio stood at 47.7x. The scrip was trading at Rs.486, up by 1.06% on Thursday.

, , , , 0 Comment
Read More
Krishna Institute reported a net profit of Rs. 79 Cr.
Business, Editorials, Equities, Health, Markets, Research - September 16, 2022

Krishna Institute reported a net profit of Rs. 79 Cr.

Krishna Institute reported a net profit of Rs. 79 Cr.

KIMS reported a net profit of Rs. 79 Cr., and decrease from Rs. 83 Cr. in March 2022 and Rs. 92 Cr. year on year. The revenue in Q1 FY22-23 increased to Rs. 459 Cr from Rs. 372 Cr in March 2021 and Rs. 473 Cr in June 2021. The operating profit was Rs. 137 in the current quarter versus Rs. 114 Cr. in the March quarter.

The expansion will be done using a cluster-based approach.

KIMS has entered into a definitive agreement to acquire a 51% stake in Kingsway Hospitals, Nagpur. This is one of the largest private multi-specialty hospitals in Nagpur, promoted by the Sancheti family and a few eminent doctors. The hospital was commissioned in 2019 with a 334-bed capacity, expandable to 500 beds. KIMS will pay upfront Rs. 800 crore for its 51% stake, which will be used to repay existing debt. After this infusion, the JV will still be left with Rs 150 Cr of debt.

Acquisition cost works out to be Rs 90 lakh/bed.

The acquisition cost works out to be Rs 90 lakh/bed. The acquisition will be completed by Sept. Assuming the operating leverage plays out, Kingsway hospital will have 250 operational beds with a 53% occupancy. For FY22 and FY23 (4 months), Kingsway generated Rs. 1700 Cr. and Rs. 47,500 Cr. of revenues, respectively. ARPOB stands at Rs 29,000/day and has turned EBIDTA positive within 3 years of operation.

KIMS management intends to enhance occupancy from current levels, as well as bring operational efficiencies and synergies. The Kingsway hospital’s COGS stands at 28-29% of sales versus KIMS’s 22% of sales. The management sees profitability scaling up from current levels and reaching 15-20% OPM over the next 2-3 years. KIMS currently has net cash of Rs 200 Cr. and thereby, the Kingsway acquisition will be funded through internal accruals. Currently, the payor mix stands at 80%, comprising of cash plus insurance.

The management, in its cluster-based approach, is looking forward to replicating the AP and Telangana models in the Maharashtra and Karnataka regions. KIMS plans to commercialise 1500 beds over the next 4–5 years across Maharashtra and the Karnataka region. The expansion will be a combination of inorganic and greenfield expansion. More importantly, the company will partner with local doctors and consultants in specific micro-markets to generate better footfalls and achieve a faster breakeven. KIMS will have full control of decision-making in such a partnership.

Valuations:

In June 2022, the EPS was Rs. 8.74, compared to Rs. 10.08 in June 2021. The ROCE and ROE were at 14.8% and 15.6%, respectively. The stock was trading at a P/E ratio of 31.7x. The debt-to-equity ratio was 0.18x, whereas the asset turnover ratio was 0.99x. The interest coverage ratio stood at 29.5x. The scrip is trading at Rs.1241, down by 0.2% on Wednesday.

Dr. Lal Pathlabs reported a net profit of Rs. 58 Cr.

, , , , 0 Comment
Read More
Business, Editorials, Equities, Health, Markets, Research - September 16, 2022

Dr. Lal Pathlabs reported a net profit of Rs. 58 Cr.

Dr. Lal Pathlabs reported a net profit of Rs. 58 Cr.

Dr. Lal Pathlabs reported a consolidated net profit declined 57% to Rs 58 crore for the first quarter June 30. The company had reported a net profit of Rs 134 crore in the April-June period of the last fiscal. The revenue from operations declined to Rs 503 crore in June 2022 from Rs 607 crore in June 2021. In Q1FY23, DLPL served 69 million patients and collected 180 million non-Covid-19 samples. The company declared an interim dividend of Rs. 6/share.

The diagnostic sector will experience tremendous growth.

Dr. Lal PathLabs reported healthy core business performance, driven by increased penetration, digitalization, enhanced testing facilities, and increased home sampling. Swasth fit contributed to 21% of total revenue; packaged tests accounted for 30% of sales. The company targets pre-Covid-19 level growth of 13-15% over the year and strives to double its volumes over 2-3 years.

The Indian diagnostic sector holds significant growth potential, as was evident by the industry’s response to the pandemic, and organised national brands have met these challenges without raising prices. The industry has seen the entry of many new competitors and the growth of the organised sector, both due to overall market growth as well as an accelerated shift from the unorganised to the organised segment.

The customers appreciate the certainty of quality and effectiveness that Dr. Lal PathLabs provides, which the unorganised players will not be able to successfully deliver. In the future, they will build and drive growth through organic expansion of lab and collection centre infrastructure, inorganic expansion, use of technology to improve customer experience, and provision of value-added services at one level while driving internal process efficiencies at another level to achieve productivity. On the organic front, the initiative of the creation of Hub Labs has started yielding good results, especially in the northern part of India. This will also give the capability to go deeper into Tier-II and Tier-III towns in large states like UP, Bihar, etc.

Valuations:

Dr. Lal Pathlabs, EPS was at Rs.6.2 in June 2022, down from Rs.15.74 in June 2021. The ROCE and ROE were at 29.4% and 25.1%, respectively. The stock was trading at a P/E ratio of 73.4x. The debt-to-equity ratio was 0.35x, whereas the asset turnover ratio was 1.04x. The interest coverage ratio stood at 12x. The scrip is trading at Rs.2389, down by 1.89% on Wednesday.

Everest Kanto reported a total revenue of Rs. 380 Cr.

, , , , , 0 Comment
Read More
Kaveri Seeds reported a net profit of Rs. 240 Cr.
Business, Editorials, Equities, Food, Markets, Research - September 16, 2022

LT FOODS reported an operating profit of Rs.166 cr.

LT FOODS reported an operating profit of Rs.166 cr.

LT Foods (LTF’s) declared its Q1 FY22-23 results with revenue rising 32.8% YOY to Rs 1,611 crore. The operating profit was up by 27.7% to Rs 166 crore and net profit went up by 23.28% YOY. Its profit margins recovered sequentially but contracted YOY. The net profit stood at Rs. 95 Cr, compared to Rs. 76 Cr. in June 2021. The revenue growth was on account of accelerated brand investments across various segments.

Margins under pressure:

The gross margin improved by 110bps YoY, aided by an improvement in product mix and higher realisation. However, EBITDA margin fell by 40 basis points year on year to 10.0% due to higher freight costs and additional brand investments.LTF has a strong focus on a value-added portfolio, which will support margin improvement in the long-term. The Health & Convenience product segments, which include ready-to-eat products, contributed 2% in FY22, an improvement from 1.5% in FY21. The company targets a 150 bps expansion in EBITDA margin through product mix, operational efficiency, and scale.
The green energy initiatives by the company will provide production efficiency. We anticipate that EBITDA margins will moderate in the near future due to higher costs, but will gradually improve thereafter. LTF’s consistent efforts on brand strengthening and distribution network expansion, as well as region and product diversification via organic and inorganic routes, have been the growth strategy.The recent acquisition in the Jasmine rice segment will strengthen market share. The re-opening of HoReCa channels is also aiding growth, while LTF’s strong focus on value-added products will improve margins.

Valuations:

LT Foods’ EPS was at Rs. 2.80 in June 2022, up from Rs. 2.27 in June 2021. The ROCE and ROE were at 14.8% and 15.6%, respectively. The stock was trading at a P/E ratio of 9.47x. The debt to equity ratio was 0.66x, whereas the asset turnover ratio was at 1.28x. The interest coverage ratio stood at 7.55x. The scrip is trading at Rs. 91.6, up by 2.92% on Monday.

, , , , , , 0 Comment
Read More
Everest Kanto reported a total revenue of Rs. 380 Cr.
Business, Editorials, Equities, Markets, Research, Uncategorized - September 12, 2022

Everest Kanto reported a total revenue of Rs. 380 Cr.

Everest Kanto reported a total revenue of Rs. 380 Cr.

The net sales stood at Rs 380.53 crore in June 2022, up 13.58% from Rs 335.02 crore in June 2021. The quarterly net profit was at Rs. 38.70 crore in June 2022, down 44.1% from Rs. 69.23 crore in June 2021. The EBITDA stands at Rs. 61.23 crore in June 2022, down 32.98% from Rs. 91.36 crore in June 2021. The company incurred a total expense of Rs. 331 Cr as compared to Rs. 257 Cr in June 2021.

Increasing CNG and Hydrogen Consumption To Drive Cylinder Demand:

Everest Kanto Cylinders Ltd. is a major player in High Pressure Seamless Steel Gas Cylinders. It generated its major revenue from India, which was around 270 Cr with a profit of Rs. 44 Cr. while the USA contributed 57 Cr. with  profit of Rs.2 Cr. The UAE reported total revenue of Rs. 51 Cr. and a net profit of Rs. 8 Cr. They manufacture a wide range of cylinders for industrial gases, medical gases, fire fighting equipment, beverage industry accumulator shells, aerospace scientific research, and CNG-NGV cylinders.

The auto OEMs have significantly reduced diesel vehicle production due to rising costs and lower demand. The Vehicle Scrappage Policy is expect to drive new vehicle sales and CNG adoption. The STCs continue to convert diesel bus fleets to CNG. CNG prices in India are link to key international benchmarks and are at  significant discount to other liquid fuels. The CNG vehicles operate at a much lower cost per km.India is a participant in the global commitment to set net zero emission targets.

Over 30 countries have released hydrogen roadmaps, committed more than USD 70 billion in public funding, and total investments are expected to exceed USD 300 billion in hydrogen spending through 2030. The government of India notified its Green Hydrogen Policy with the aim of making India a Green Hydrogen Hub. This involves scaling up the use of domestically produced hydrogen to significantly reduce energy imports. The policy is in line with the country’s pledge to be carbon neutral by 2070. India’s hydrogen demand is expected to increase five-fold by 2050, from 6 MPTA in 2020. 80% of the demand in 2050 is expected to be green in nature.

Valuations:

Everest Kanto EPS has decreased to Rs. 3.45 in June 2022 from Rs. 6.17 in June 2021. The debt to equity ratio was 0.14x, whereas the asset turnover ratio was at 0.8x. The interest coverage ratio was at 33.6x compared to 6.3 in June 2021. This was due to a reduction in debt. The scrip is trading at Rs. 123, up by 5% on Monday.

 

 

 

HUL Q1 FY23 Result Update: HUL beats estimates with Rs 2,381-cr net profit in Q1; revenue up 19.6%

, , , , 0 Comment
Read More
Nestle India reported a net profit of Rs. 515 crores:
Business, Editorials, Equities, Markets, Research - September 7, 2022

Nestle India reported a net profit of Rs. 515 crores:

Nestle India reported a net profit of Rs. 515 crores:

Nestle India reported a total revenue growth of 16.1% YoY and 1.4% QoQ to Rs. 4036.6 crores. The net profit decreased by 4.3% YoY and 13.3% QoQ to Rs. 515.3 crores. Domestic sales increased by 16.4% with a healthy balance of pricing and volume & mix, and export sales increased by 0.7%. The cost of materials increased due to inflation, particularly edible oil, milk and its derivatives, and packaging materials, partly offset by better realizations. The 15% raw material inflation led to a 304bps decline in gross margins, to 54.0%. The EBITDA decreased by 3.4% YoY and 11.4% QoQ to Rs. 819.5 crores, while the EBITDA margin came in at 20.3%, which declined by 409bps YoY and 293bps QoQ.

Maintaining steady growth through the launch of new products.

The milk products and nutrition sectors witnessed double-digit growth, driven by strong growth in the Milkmaid brand. The out-of-home categories such as confectionaries and liquid beverages registered a strong growth of above 20% on the back of the opening up of offices and business-led initiatives, while the food category continued its strong double-digit streak of growth with improved market share in MAGGI Noodles. The company continued to see strong momentum in megacities and metros, as well as strong acceleration across smaller towns and classes.

Nestle is continuously focusing on entering new categories to maintain its consistent growth momentum in the medium to long term. The company acquired the pet food business of Purina Petcare India Pvt. Ltd. (PFB) from its parent entity Nestlé S.A. for Rs. 123.5 crores. The pet food business (PFB) has evolved very positively and has an exciting future with pet adoption on the rise post-pandemic. PFB has clocked a CAGR of 39.4% over CY18–21 and a turnover of Rs. 36 crores in FY22, valued at a price-to-sales ratio of 3.4x its sales. It derived 14% of its sales from the e-commerce channel. The pet food market in India has been estimated at Rs. 4,000 crores, with dry dog food comprising 75% of the category.
Going forward, leveraging Nestlé India’s network would further accelerate the growth of the pet food business in India. Nestle India Ltd. (NIL) is the market leader in instant noodles and baby food products in India and the No. 2 player in the instant coffee and chocolate segment. One of the most interesting aspects of NIL in recent years has been the spontaneous pace of launches. Since 2016, NIL has launched over 90 products across segments, including new launches as well as variants to boost volume growth and market share gain, with 20 projects in the pipeline.

Nestle continues to focus on innovation to drive growth. New launches across segments have led to strong volume growth over the last few years. The management stated that innovation will be undertaken across product categories and that some of the products launched in the global market can also be introduced in the domestic market. The company is also considering adding new categories that will add value to its existing portfolio. It is expected that the aggressive pace of new innovations, the success of new launches, and the improvement in demand could further accelerate the company’s growth. The major risks for the NIL are increased competitive intensity, rising input prices with an inability to pass on the same, and higher-than-expected A&P spending.

Valuations:

NIL will continue to deliver strong growth going forward as well and will gain share in the core categories, led by distribution expansion, further strengthening of its position in rural areas with the launch of new products backed by R&D capabilities, and growth in the premium portfolio. These factors, along with market leadership in 80% of its categories, mean the company has enough pricing power to further drive premiumization along with volume growth. The EPS was Rs. 53 in the June quarter. The stock is trading at a PE ratio of 80x. The EBITDA was at 50.4x. The ROCE and ROE stood at 147% and 113%, respectively. The stock was trading at Rs. 19196 on September 7th, down by 0.81%.

, , 0 Comment
Read More
Vodafone Idea reported lower margins-
Business, Equities, Research Reports - September 6, 2022

Vodafone Idea reported lower margins-

Vodafone Idea reported lower margins

Vodafone Idea reported a consolidated loss of Rs 7,295 crore in the June quarter as against Rs 7,312 crore in June 2021. The total revenue stood at Rs 10,410 crore, a YoY growth of 13.7%. The revenue metric improvement was largely a function of residual tariff hike pass-through and one extra day during the quarter, which led to 3.2% QoQ growth. Vodafone Idea’s ARPU for the quarter improve by 23.4 percent YoY to Rs 128, aided by tariff hikes. 

 

Restricted Competitiveness:

The subscriber base declined from 3.4 million to 240.4 million, with a churn rate of 3.5%. The 4G sub-base saw an addition of merely 0.9 million QoQ to 119 million. Data traffic/MOU increased 4%, 2% QoQ to 5.4 GB, 620 minutes, respectively. Data usage and subscriptions increased 4% year on year to 13.3 GB, but remained lower than peers, who use nearly 20 GB per month. Similarly, capex was at 840 crore vs. 1210 crore in Q4. The management reiterated its intent to raise tariffs by the end of the current calendar year, which will lead to a rise in ARPU. The net debt, at 1.982 lakh crore, was up by 1820 crore QoQ. The net debt includes deferred spectrum liability of 1.166 lakh crore, AGR liability of 67270 crore, and bank borrowing of 15200 crore. While the recent government measures ensure the survival of VIL, staying competitive will be a function of how quickly it raises funds. Substantial fundraising to meet capital spending to expand 4G network coverage, launch 5G and stay competitive  Improvements in subscriber churn and 4G subscriber metrics Many key risks for the company are its inability to raise funds and expand coverage to compete.

The company has acquired mid-band 5G spectrum in 17 priority circles and mmWave 5G spectrum in 16 circles. It has also acquired an additional 4G spectrum in three circles, i.e., in Andhra Pradesh, Karnataka, and Punjab, for 18799 crores, payable in 20 annual instalments of 1681 crores per annum. It did not specify any time frame for the 5G launch. The company expects cash EBITDA to improve as 5G spectrum deployment occurs. It will result in a reduction in SUC charges, while there will be some lower tower rent benefits. The Board of Directors has approved the allotment of 42.77 crore warrants to Vodafone Group on a preferential basis. This, coupled with the earlier preferential raise in Q4 of  4500 crore, takes the total fund infusion by the promoter groups to 4986 crore, largely to pay Indus Tower dues. The company recently agreed to convert interest accrued from the four-year moratorium into equity. It indicated that DoT has confirmed the NPV of Rs 16,300 crore. This equity conversion will lead to dilution with the government owning 33% in VIL and the promoters (Vodafone and Aditya Birla group) owning 50%.

Key Triggers

The outstanding debt will come down by a similar amount, with an annual interest cost savings of Rs 1200 crore from the same. The government also has the discretion to convert total deferred moratorium dues into equity at the end of four years. The guidelines for this are still awaited. VIL remains the weakest private telco. The need for capitalization is urgent, owing to the company’s impending debt repayment, lagging network spending, and continued relative market share loss. It is highlighted that recent government relief measures would ensure the survival of VIL, but the future growth outlook remains uncertain.

Valuations:

In the June quarter, the EPS was Rs. 2.27).The stock is trading at a PE ratio of 86.2x. The EBITDA was at 3.97x with an interest coverage ratio of 0.30x. The stock was trading at Rs. 9.28 on Septembe up by 3.69%.

, , , , , , 0 Comment
Read More
FII Selling Driven by US Interest Rates, Not China
Business, Markets, Result Updates - August 30, 2022

Saregama PAT was Rs. 41 cr. in Q1 FY23.

Saregama PAT was Rs. 41 cr. in Q1 FY23.

PAT increased by 52% year on year to Rs. 41 Cr. in Q1 FY23. The company’s operating revenue rose 61% YoY to Rs. 169 Cr. in Q1 FY23. Saregama’s operating income before content charge, interest and depreciation (OIBCID) rose 54% to Rs. 64 r. in Q1 FY23 from Rs. 42 Cr. in the corresponding quarter last year. The Q1 FY23 PBT stood at Rs. 55 Cr. as against Rs. 36 Cr. in the corresponding quarter last year, with a 52% growth YoY.

Current and future quarter work:

During this quarter, the company launched the music of Mahesh Babu’s Sarkaru Vaari Paata in Telugu; Operation Romeo and Ittu Si Baat in Hindi with music from singers like Arijit Sigh and Jubin Nautiyal. Saregama also released multiple “Originals” songs sung by Neeti Mohan, Stebin Ben, etc. Overall, the company released 186 films and non-film songs across Hindi, Bhojpuri, Gujarati, Punjabi, Tamil, Telugu, Malayalam, Marathi, and Bengali languages. The other highlight of the quarter was the use of songs by brands like Dabur, Vogue Eyewear, TVF, One Card, PhonePe, etc. in their ad films.

With retail markets opening up, Carvaan continued to regain its momentum. The company sold 98k units in Q1, compared to 45k last year. During the last fortnight of June, they also started test marketing two new variants, namely, Music Bar with Karaoke and Carvaan Mobile.

They have completed shooting of our first Malayalam film, “Padavettu,” starring Nivin Pauly. The shooting begins for the next Malayalam film “Kaapa” starring the superstar Prithviraj Sukumaran and the shooting of the first Punjabi film “Oye Makhana” starring Amy Virk. “Hunter-The Invisible Women”, starring Suniel Shetty, is expected to be released soon. Roja and Anbe Vaa are the slot leaders in their respective prime time slots. The Saregama TV Shows YouTube channel garnered 38 million views in Q1FY23. Star India has licensed the remake rights of the TV series “Roja” for the Hindi language. The company continues to create short video content relating to “Bhakti” and “Yoga” exclusively for YouTube. In addition to concerts, the vertical will develop musical theatre IP based on the stories and songs of some of the greatest films in our catalogue, like Disco Dancer and Karz.

Valuations:

The company has reported an EPS of Rs. 2.15 for the period ended June 30, 2022 as compared to Rs. 1.56 for the period ended June 30, 2021. The ROCE and ROE stood at 22.1% and 16.2%, respectively. The stock is trading at a P/E of 46.4x, which is not expensive, and a 5-year P/E of 24.7x. Saregama has an EBITDA multiple of 30.4x and an interest coverage ratio of 43.6x. The price to book ratio is at 5.61x, which has a book value of Rs.71.4. The scrip was trading at Rs. 401, down by 1.43% on Monday.

, , , , 0 Comment
Read More